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Sthe more extreme cases. Published reports of LSD have been small single centre
series. We therefore sought to collect a large series of LSD cases from multiple centres
to compare to the cases reported in the MAUDE database.
Methods: Two experienced interventional cardiologists analysed angiographic images
and case histories of 59 LSD cases from 6 high volume European Centres (multicentre
case series MCCS). These cases were compared to the 105 individual reports of cases
identiﬁed from the MAUDE database (MAUDE series). The analysis included
mechanism and location of LSD, stent type, and clinical outcome. Mechanism of LSD
was divided into guide catheter induced LSD, and secondary device induced LSD.
Results: In both series, LSD occurred infrequently with circumﬂex interventions (7%),
2.25mm diameter stents (6%) and < 10mm length stents (3%). Lesion calciﬁcation (35%
cases) and tortuosity (30% cases) were common. LSD occurred at the proximal edge alone
in>80%cases.Guide catheter inducedLSDwas less commonin theMAUDEseries (17%)
than the MCCS (62%, p<0.001). Element-type stents were involved in guide catheter
induced LSD in 75% cases and secondary device LSD in 82% cases. Major complications
occurred more frequently in theMAUDE series (13%) than theMCCS (2%, p¼0.04), and
were more frequent (33% MCCS, 67% MAUDE) if the LSD was untreated than if
re-ballooning/stenting was performed (0% MCCS, 6%MAUDE; p<0.0001).
Conclusions: LSD usually occurred at the proximal end of the stent, was associated
with complex disease and occurred infrequently with small stents and circumﬂex
interventions. The Element-type platform was the commonest stent involved in both
guide catheter and secondary device LSD. In the MAUDE series guide catheter LSD
was under-represented and cases involving major complications were over-repre-
sented. Major complications including stent thrombosis, emergency CABG and death
were much commoner if the stent was not / could not be re-expanded.
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Background: There are limited data on treatment and long-term clinical outcome after
deﬁnitive (angiographically conﬁrmed) stent thrombosis (ST).
Methods: Retrospective analysis of baseline characteristics and procedural and clin-
ical outcomes in patients with angiographically conﬁrmed ST (ARC classiﬁcation)
from a cohort of 8069 consecutive unselected patients treated by PCI in a single centre
(June 2000-December 2012).
Results: One hundred thirty consecutive patients with deﬁnite ST were included in the
analysis (1.6%). a) Main baseline characteristics: male sex 82.3%; age 6313; dia-
betes 38.5%; previous renal failure 23.1%; previous AMI 69.2%, peripheral arterial
disease (PAD) 16.6%. Clinical presentation was ST-segment elevation myocardial
infarction in 68% and cardiogenic shock in 13%. Mean time from stent implantation to
ST was 6361168 days. According to ARC classiﬁcation, 14.6% were acute; 35.4%
subacute; 14.6% late and 35.4% very late. Previous implanted stent was DES in
39.2%. b) Main procedural characteristics: IIbIIIa inhibitors were used in 66.2%;
IVUS guidance in 44.6%; manual thrombectomy in 70.8%; new stent implantation in
74.6%. c) Main clinical outcomes: in-hospital mortality was 9.2% and one-year
mortality was 12.3%. Two patients (1.5%) experienced recurrent ST on follow-up.
Type of previously implanted stent (DES or BMS), time of ST (acute, subacute, late or
very late), vessel treated and DES implantation for ST treatment were not related to
mortality on follow-up. Independent predictors for one-year mortality were age, PAD,
cardiogenic shock on admission and multivessel disease.
Conclusions: In a cohort of real-life consecutive patients, PCI for ST was relatively
infrequent. Patients presenting with ST had high comorbidity levels. Up to one third of
patients had very late ST. Nearly half of the PCI were IVUS-guided. One-year
mortality and recurrent ST on follow-up was lower than previously reported; this may
be explained by the high rate of IVUS-guided PCI.
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Background: Endeavor Resolute drug-eluting stent (ER-DES) has been used
worldwide in many cath labs as standard DES during the last years. FDA have
recently approved Resolute Integrity stent (RI-DES) which is based on different stentB146 JACC Vol 62/18/Suppl B j October 27–November 1, 20platform. There is little clinical data in regard to safety and efﬁcacy outcomes between
these two stents after a direct comparison in unselected patients. Our aim was to
compare ER-DES with RI-DES stent in regard to occurrence of in-stent restenosis and
stent thrombosis in unselected consecutive patients.
Methods: Information was obtained from the SCAAR registry (Swedish Coronary
Angiography and Angioplasty Registry) for the procedures performed in Västra
Götaland County in Western Sweden. The database contains information about all
consecutive procedures performed at ﬁve PCI centers with approximately 3000 PCI/
year. ER-DES was used from 2008 with complete switch in the whole region to RI-
DES in 2011. All procedures performed between 2008-2013 for stable angina,
unstable angina, non-STEMI and STEMI were included in the analysis. The two stents
were compared using propensity score-adjusted multilevel Cox proportional-hazards
regression with stents as primary observation units. The following confounders were
included in the calculation of propensity score: age, gender, indication for PCI,
smoking habits, hypertension, diabetes, hyperlipidaemia, stent diameter, stent length,
stenosis class and procedural success.
Results: Between 2008 and 2013, 614 ER-DES and 1858 RI-DES were implanted to
929 patients in 1327 procedures. There were 49 events in total of which 24 cases were
in-stent restenosis and 25 cases were stent thrombosis. The use of RI-DES was
associated with decreased risk for in-stent restenosis/stent thrombosis at one-year (HR
0.42; 95% CI 0.21 – 0.86; P¼0.017).
Conclusions: In this registry study RI-DES shows a lower frequency of in-stent
restenosis and stent thrombosis compared to ER-DES. Improvement in DES stent
design may provide substantial clinical beneﬁt to the patients undergoing PCI. "Real
world" registries are an important tool in continuous evaluation of new devices and
interventions and for support in decision-making within health-care systems.
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Background: Drug-eluting stents (DES) reduced restenosis. Though rare, in-stent
restenosis (ISR) followed by a new ISR (resistant ISR, R-ISR) represents a chal-
lenging PCI complication. Whether angiographic patterns of R-ISR are indicative of
clinical outcomes is unknown.
Methods: Resistant ISR (R-ISR) was deﬁned as the 2nd episode of ISR after
treatment of the 1st ISR. We reviewed 201 consecutive patients with DES pre-
senting with R-ISR from 2003 to 2011. Angiograms were reviewed by a core lab
for patterns of the 1st and 2nd ISR based on Mehran classiﬁcation. We examined
1-year death, MI, revasc (TVR and TVF), and major adverse cardiac events
(MACE).
Results: In 201 patients, 77% had focal and 23% diffuse R-ISR. Focal intrastent (IC)
and diffuse intrastent (II) were prevalent patterns of focal and diffuse R-ISR (50% and
42% respectively). Groups were balanced with similar demography and angiography.
Within groups original implanted stents were SES (44% vs 56%), PES (32% vs 22%),
ZES (0% vs 8.5%), and EES (23% vs 14%) respectively. At 1 year, mortality was
higher in diffuse R-ISR patients (9% vs 4.5%, p¼0.06), but MACE was comparable
between groups (25% vs 29%, p¼0.59, Figure 1). Correlates of revasc were R-ISR
within 1-year of the index procedure (HR: 1.8, 95% CI 0.99-3.3, P¼0.05) and female
sex (1.62 0.97-2.71, P¼0.06).
Conclusions: Resistant ISR is a rare complication of PCI even with newer DES.
Though MI, TVR/TVF, and MACE did not differ signiﬁcantly, those with diffuse R-
ISR patterns had 2-fold the mortality rate than those with focal R-ISR. In the DES era,
diffuse R-ISR still results in worse clinical outcomes.13 j TCT Abstracts/POSTER/In-stent Restenosis and Stent Thrombosis
